Joseph E. Tomaszewski

6.6k total citations
140 papers, 4.6k citations indexed

About

Joseph E. Tomaszewski is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Joseph E. Tomaszewski has authored 140 papers receiving a total of 4.6k indexed citations (citations by other indexed papers that have themselves been cited), including 68 papers in Molecular Biology, 50 papers in Oncology and 26 papers in Cancer Research. Recurrent topics in Joseph E. Tomaszewski's work include Cancer therapeutics and mechanisms (29 papers), PARP inhibition in cancer therapy (17 papers) and DNA Repair Mechanisms (15 papers). Joseph E. Tomaszewski is often cited by papers focused on Cancer therapeutics and mechanisms (29 papers), PARP inhibition in cancer therapy (17 papers) and DNA Repair Mechanisms (15 papers). Joseph E. Tomaszewski collaborates with scholars based in United States, Malaysia and United Kingdom. Joseph E. Tomaszewski's co-authors include James H. Doroshow, Ralph E. Parchment, Robert J. Kinders, Shivaani Kummar, Larry Rubinstein, Edward A. Sausville, Beverly A. Teicher, Anthony Dipple, Percy Ivy and C. Anita H. Bigger and has published in prestigious journals such as Science, Journal of the American Chemical Society and Journal of Clinical Oncology.

In The Last Decade

Joseph E. Tomaszewski

136 papers receiving 4.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Joseph E. Tomaszewski United States	36	2.4k	1.5k	789	463	429	140	4.6k
William N. Hait United States	38	2.8k 1.2×	2.0k 1.3×	691 0.9×	365 0.8×	233 0.5×	92	4.8k
Melinda G. Hollingshead United States	45	3.9k 1.6×	1.9k 1.2×	1.2k 1.5×	493 1.1×	357 0.8×	167	6.9k
Ching‐Shih Chen United States	44	4.7k 2.0×	1.0k 0.7×	682 0.9×	616 1.3×	263 0.6×	144	6.8k
Haiying Chen United States	31	2.7k 1.1×	1.0k 0.7×	764 1.0×	476 1.0×	204 0.5×	129	4.8k
Raymond J. Hohl United States	40	2.3k 1.0×	1.5k 1.0×	818 1.0×	446 1.0×	117 0.3×	138	4.9k
Jan H. Beumer United States	40	2.3k 1.0×	2.1k 1.4×	489 0.6×	417 0.9×	261 0.6×	234	4.8k
Christopher L. Morton United States	45	3.2k 1.3×	1.5k 1.0×	663 0.8×	238 0.5×	475 1.1×	128	5.6k
Michelle A. Rudek United States	48	3.8k 1.6×	2.5k 1.7×	1.2k 1.5×	359 0.8×	261 0.6×	239	7.2k
Liang Cao China	44	4.0k 1.6×	2.1k 1.4×	954 1.2×	748 1.6×	475 1.1×	241	8.0k
Sanjay Goel United States	37	1.7k 0.7×	2.9k 1.9×	549 0.7×	520 1.1×	442 1.0×	269	5.2k

Countries citing papers authored by Joseph E. Tomaszewski

Since Specialization

Citations

This map shows the geographic impact of Joseph E. Tomaszewski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joseph E. Tomaszewski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joseph E. Tomaszewski more than expected).

Fields of papers citing papers by Joseph E. Tomaszewski

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joseph E. Tomaszewski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joseph E. Tomaszewski. The network helps show where Joseph E. Tomaszewski may publish in the future.

Co-authorship network of co-authors of Joseph E. Tomaszewski

This figure shows the co-authorship network connecting the top 25 collaborators of Joseph E. Tomaszewski. A scholar is included among the top collaborators of Joseph E. Tomaszewski based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joseph E. Tomaszewski. Joseph E. Tomaszewski is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Balasubramanian, Priya, Robert J. Kinders, Shivaani Kummar, et al.. (2017). Antibody-independent capture of circulating tumor cells of non-epithelial origin with the ApoStream® system. PLoS ONE. 12(4). e0175414–e0175414. 48 indexed citations

Srivastava, Apurva K., Melinda G. Hollingshead, Jennifer Weiner, et al.. (2016). Pharmacodynamic Response of the MET/HGF Receptor to Small-Molecule Tyrosine Kinase Inhibitors Examined with Validated, Fit-for-Clinic Immunoassays. Clinical Cancer Research. 22(14). 3683–3694. 24 indexed citations

Avtanski, Dimiter, Arumugam Nagalingam, Joseph E. Tomaszewski, et al.. (2016). Indolo‐pyrido‐isoquinolin based alkaloid inhibits growth, invasion and migration of breast cancer cells via activation of p53‐miR34a axis. Molecular Oncology. 10(7). 1118–1132. 20 indexed citations

Srivastava, Apurva K., Melinda G. Hollingshead, Jeevan Prasaad Govindharajulu, et al.. (2015). Effect of a Smac Mimetic (TL32711, Birinapant) on the Apoptotic Program and Apoptosis Biomarkers Examined with Validated Multiplex Immunoassays Fit for Clinical Use. Clinical Cancer Research. 22(4). 1000–1010. 19 indexed citations

Teicher, Beverly A. & Joseph E. Tomaszewski. (2015). Proteasome inhibitors. Biochemical Pharmacology. 96(1). 1–9. 142 indexed citations

Kummar, Shivaani, Jiuping Ji, Robert J. Morgan, et al.. (2012). A Phase I Study of Veliparib in Combination with Metronomic Cyclophosphamide in Adults with Refractory Solid Tumors and Lymphomas. Clinical Cancer Research. 18(6). 1726–1734. 155 indexed citations

Kinders, Robert J., Melinda G. Hollingshead, Scott M. Lawrence, et al.. (2010). Development of a Validated Immunofluorescence Assay for γH2AX as a Pharmacodynamic Marker of Topoisomerase I Inhibitor Activity. Clinical Cancer Research. 16(22). 5447–5457. 56 indexed citations

Pfister, Thomas D., Ralph E. Parchment, Shivaani Kummar, et al.. (2010). Monitoring Drug-Induced γH2AX as a Pharmacodynamic Biomarker in Individual Circulating Tumor Cells. Clinical Cancer Research. 16(3). 1073–1084. 75 indexed citations

Chen, Helen X., James R. Wright, Susan L. Holbeck, et al.. (2010). Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements. Nature Reviews Drug Discovery. 9(11). 843–856. 189 indexed citations

10.

Pfister, Thomas D., William C. Reinhold, Keli Agama, et al.. (2009). Topoisomerase I levels in the NCI-60 cancer cell line panel determined by validated ELISA and microarray analysis and correlation with indenoisoquinoline sensitivity. Molecular Cancer Therapeutics. 8(7). 1878–1884. 126 indexed citations

11.

Kummar, Shivaani, Larry Rubinstein, Robert J. Kinders, et al.. (2009). Abstract #5456: Correlation between inhibition of the activity of poly(ADP-ribose) polymerase (PARP) in human peripheral blood mononuclear cells (PBMCs) and tumor biopsies following treatment with ABT-888, an inhibitor of PARP. Cancer Research. 69. 5456–5456. 6 indexed citations

12.

Yang, Sherry X., Shivaani Kummar, Seth M. Steinberg, et al.. (2009). Immunohistochemical detection of poly(ADP-ribose) polymerase inhibition by ABT-888 in patients with refractory solid tumors and lymphomas. Cancer Biology & Therapy. 8(21). 2004–2009. 21 indexed citations

13.

Pfister, Thomas D., Sonny Khin, Melinda G. Hollingshead, et al.. (2008). Development and preclinical modeling of a topoisomerase I pharmacodynamic immunoassay for use in clinical trials. Clinical Cancer Research. 14. 1 indexed citations

14.

Tomaszewski, Joseph E., et al.. (2008). CD4+ T cells recognizing a single self-peptide expressed by APCs induce spontaneous autoimmune arthritis. The Journal of Immunology. 180(10). 7047–7047. 2 indexed citations

15.

Kinders, Robert J., Melinda G. Hollingshead, Scott M. Lawrence, et al.. (2007). Development and validation of a quantitative assay for γH2AX in needle biopsies using topoisomerase I inhibitors. Molecular Cancer Therapeutics. 6. 1 indexed citations

16.

Ji, Jay, Ravithat Putvatana, Yiping Zhang, et al.. (2007). A validated assay for gamma-H2AX as a pharmacodynamic biomarker of response to DNA damage. Cancer Research. 67. 4027–4027. 1 indexed citations

17.

Zahalka, Eias, et al.. (2007). Pilot toxicity study of indenoisoquinoline analogs (NSC-725776 and NSC-724998) in beagle dogs. Cancer Research. 67. 1562–1562. 2 indexed citations

18.

Hollingshead, Melinda G., Suzanne Borgel, John Carter, et al.. (2007). Evidence of in vivo efficacy for the indenoisoquinolines linked with pharmacodynamic markers for γH2AX. Molecular Cancer Therapeutics. 6. 1 indexed citations

19.

Johnson, William D., et al.. (2006). A pharmacokinetic/pharmacodynamic approach to evaluating the safety of zebularine in non-human primates. Cancer Research. 66. 309–309. 10 indexed citations

20.

Cheng, Xun, Young G. Shin, Barry Levine, et al.. (2003). Quantitative analysis of betulinic acid in mouse, rat and dog plasma using electrospray liquid chromatography/mass spectrometry. Rapid Communications in Mass Spectrometry. 17(18). 2089–2092. 35 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact